Abcellera Biologics Inc
ABCL5.570USD
+0.210+3.92%
交易中 （美东）报价延迟15分钟
1.66B总市值
亏损市盈率 TTM
关于 Abcellera Biologics Inc 公司
AbCellera Biologics Inc. 发现和开发用于治疗癌症、代谢和内分泌疾病以及自身免疫性疾病等治疗领域的抗体药物。该公司的引擎整合了技术、数据科学、基础设施和跨学科团队，以解决抗体发现问题。该公司已经开发了技术平台来解锁药物类别、靶点和模式，包括跨膜蛋白、T 细胞接合剂和肽-MHC。该公司专注于推进内部项目管线并与合作伙伴合作开展药物开发项目。其内部管线中的前两个临床前项目是 ABCL575 和 ABCL635。ABCL635 是一种针对未公开靶点的抗体药物候选物，适用于代谢和内分泌疾病。ABCL575 靶向 OX40 配体，正在开发用于治疗特应性皮炎和其他自身免疫和炎症适应症的疗法。
Abcellera Biologics Inc简介
公司代码ABCL
公司名称Abcellera Biologics Inc
上市日期Dec 11, 2020
CEODr. Carl L.G. Hansen, Ph.D.
员工数量596
证券类型Ordinary Share
年结日Dec 11
公司地址150 W 4Th Avenue
城市VANCOUVER
上市交易所NASDAQ Global Select Consolidated
国家Canada
邮编V5Y 1G6
电话16045599005
网址https://www.abcellera.com/
公司代码ABCL
上市日期Dec 11, 2020
CEODr. Carl L.G. Hansen, Ph.D.
Abcellera Biologics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Andrew W. Lo, Ph.D.
Dr. Andrew W. Lo, Ph.D.
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Andrew W. Lo, Ph.D.
Dr. Andrew W. Lo, Ph.D.
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2024Q2
FY2023Q2
业务USD
名称
营收
占比
Licensing revenue
10.45M
61.14%
Research fees
6.64M
38.86%
暂无数据
业务
地区
业务USD
名称
营收
占比
Licensing revenue
10.45M
61.14%
Research fees
6.64M
38.86%
股东统计
更新时间: 10月12日 周日
更新时间: 10月12日 周日
持股股东
股东类型
持股股东
持股股东
占比
Thermopylae Holdings Ltd
18.79%
Baker Bros. Advisors LP
9.21%
Capital World Investors
4.47%
Baillie Gifford & Co.
3.47%
Lecault (Veronique)
3.22%
其他
60.85%
持股股东
持股股东
占比
Thermopylae Holdings Ltd
18.79%
Baker Bros. Advisors LP
9.21%
Capital World Investors
4.47%
Baillie Gifford & Co.
3.47%
Lecault (Veronique)
3.22%
其他
60.85%
股东类型
持股股东
占比
Corporation
18.79%
Hedge Fund
16.22%
Investment Advisor
15.98%
Individual Investor
4.15%
Investment Advisor/Hedge Fund
2.97%
Bank and Trust
1.20%
Private Equity
1.13%
Research Firm
0.62%
Venture Capital
0.32%
其他
38.61%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
319
114.85M
38.43%
-43.37M
2025Q2
372
214.57M
71.89%
-123.81K
2025Q1
429
202.31M
67.85%
-22.54M
2024Q4
453
194.86M
65.41%
-21.40M
2024Q3
451
190.45M
64.55%
-29.37M
2024Q2
449
195.17M
66.27%
-23.48M
2024Q1
442
202.34M
69.21%
-22.49M
2023Q4
434
206.18M
71.07%
-38.61M
2023Q3
437
216.53M
74.89%
-39.50M
2023Q2
439
222.03M
76.83%
-29.38M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Thermopylae Holdings Ltd
56.14M
18.79%
--
--
Apr 01, 2025
Baker Bros. Advisors LP
27.53M
9.21%
--
--
Jun 30, 2025
Capital World Investors
13.36M
4.47%
--
--
Jun 30, 2025
Baillie Gifford & Co.
10.36M
3.47%
-835.83K
-7.47%
Jun 30, 2025
Lecault (Veronique)
9.61M
3.22%
--
--
Apr 01, 2025
Two Sigma Investments, LP
8.18M
2.74%
+2.41M
+41.75%
Jun 30, 2025
UBS Asset Management (Americas) LLC
5.00M
1.67%
-1.61M
-24.41%
Jun 30, 2025
ArrowMark Colorado Holdings, LLC
4.11M
1.37%
--
--
Jun 30, 2025
UBS Asset Management (Switzerland)
3.48M
1.16%
-5.59M
-61.65%
Jun 30, 2025
UBS Switzerland AG
3.43M
1.15%
-1.62M
-32.07%
Jun 30, 2025
查看更多
持股ETF
更新时间: 10月2日 周四
更新时间: 10月2日 周四
机构名称
占比
iShares Genomics Immunology and Healthcare ETF
2.11%
Virtus LifeSci Biotech Clinical Trials ETF
1.03%
ProShares Ultra Nasdaq Biotechnology
0.13%
Invesco Nasdaq Biotechnology ETF
0.13%
iShares Biotechnology ETF
0.09%
SPDR S&P International Small Cap ETF
0.08%
Invesco RAFI Developed Mkts ex-US SM ETF
0.03%
Avantis US Small Cap Equity ETF
0.01%
SPDR Portfolio Developed World ex-US ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
查看更多
iShares Genomics Immunology and Healthcare ETF
占比2.11%
Virtus LifeSci Biotech Clinical Trials ETF
占比1.03%
ProShares Ultra Nasdaq Biotechnology
占比0.13%
Invesco Nasdaq Biotechnology ETF
占比0.13%
iShares Biotechnology ETF
占比0.09%
SPDR S&P International Small Cap ETF
占比0.08%
Invesco RAFI Developed Mkts ex-US SM ETF
占比0.03%
Avantis US Small Cap Equity ETF
占比0.01%
SPDR Portfolio Developed World ex-US ETF
占比0.01%
Fidelity Nasdaq Composite Index ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
